Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedApr 01, 2026
DataAggregated Company Financials
Companies317
  • 7D3.0%
  • 3M1.2%
  • 1Y28.1%
  • YTDn/a

Over the last 7 days, the Pharma industry has remained flat, although notably Johnson & Johnson gained 3.9%. As for the the longer term, the industry is up 21% over the past 12 months. Looking forward, earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Apr 2026US$2.2tUS$405.9bUS$71.7b16.7x30.9x5.5x
Fri, 27 Feb 2026US$2.4tUS$405.8bUS$72.3b19.9x33x5.9x
Sun, 25 Jan 2026US$2.3tUS$404.7bUS$73.2b19.8x31.4x5.7x
Tue, 23 Dec 2025US$2.2tUS$402.8bUS$71.4b19.9x31.3x5.5x
Thu, 20 Nov 2025US$2.1tUS$402.7bUS$71.4b19.4x29.9x5.3x
Sat, 18 Oct 2025US$1.9tUS$389.2bUS$63.5b17.6x29.5x4.8x
Mon, 15 Sep 2025US$1.8tUS$387.9bUS$60.9b18.9x29.3x4.6x
Wed, 13 Aug 2025US$1.6tUS$387.9bUS$60.7b18.8x27.1x4.2x
Fri, 11 Jul 2025US$1.8tUS$382.7bUS$61.3b18.2x28.8x4.6x
Sun, 08 Jun 2025US$1.7tUS$382.7bUS$61.2b17.1x28.1x4.5x
Tue, 06 May 2025US$1.8tUS$382.8bUS$63.7b17.1x27.8x4.6x
Thu, 03 Apr 2025US$1.8tUS$379.9bUS$41.2b16.7x43.1x4.7x
Sat, 01 Mar 2025US$1.9tUS$381.1bUS$39.3b16.7x49.1x5.1x
Mon, 27 Jan 2025US$1.8tUS$370.4bUS$30.5b18.4x59.1x4.9x
Wed, 25 Dec 2024US$1.8tUS$369.4bUS$31.1b17.3x58.4x4.9x
Fri, 22 Nov 2024US$1.8tUS$373.8bUS$30.6b19.3x58.8x4.8x
Sun, 20 Oct 2024US$2.0tUS$365.3bUS$23.7b18.6x85.8x5.6x
Tue, 17 Sep 2024US$2.0tUS$364.3bUS$25.4b19x80.2x5.6x
Thu, 15 Aug 2024US$2.0tUS$362.0bUS$21.9b17.1x90.6x5.5x
Sat, 13 Jul 2024US$2.0tUS$357.7bUS$13.8b15.9x145.3x5.6x
Mon, 10 Jun 2024US$1.9tUS$358.3bUS$14.1b15.6x136.5x5.4x
Wed, 08 May 2024US$1.9tUS$357.9bUS$13.8b21.7x134.6x5.2x
Fri, 05 Apr 2024US$1.9tUS$355.2bUS$22.7b24.6x82.9x5.3x
Sun, 03 Mar 2024US$1.9tUS$355.3bUS$22.5b24.1x85x5.4x
Tue, 30 Jan 2024US$1.8tUS$375.2bUS$33.9b25.3x52.1x4.7x
Thu, 28 Dec 2023US$1.7tUS$375.2bUS$33.8b32.1x49.8x4.5x
Sat, 25 Nov 2023US$1.7tUS$375.1bUS$33.9b26.2x48.8x4.4x
Mon, 23 Oct 2023US$1.7tUS$382.7bUS$44.7b17.6x37x4.3x
Wed, 20 Sep 2023US$1.7tUS$381.8bUS$43.9b18.6x39.2x4.5x
Fri, 18 Aug 2023US$1.8tUS$381.7bUS$44.0b20.2x40.2x4.6x
Sun, 16 Jul 2023US$1.7tUS$392.8bUS$60.2b18.3x27.7x4.2x
Tue, 13 Jun 2023US$1.7tUS$392.8bUS$60.1b19x28.6x4.4x
Thu, 11 May 2023US$1.8tUS$394.9bUS$57.5b19.8x30.4x4.4x
Sat, 08 Apr 2023US$1.7tUS$401.2bUS$69.7b15.9x23.7x4.1x
Price to Earnings Ratio

23.7x


Total Market Cap: US$1.7tTotal Earnings: US$69.7bTotal Revenue: US$401.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.6x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 30.7x which is lower than its 3-year average PE of 53.6x.
  • The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 5.4x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Comparison

How does U.S. Pharma compare with similar industries?

US Market-0.61%
Healthcare1.34%
Pharma2.99%
Pharma2.99%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
JNJ Johnson & JohnsonUS$244.443.9%
+US$22.1b		59.5%PE22x
LLY Eli LillyUS$919.771.9%
+US$15.0b		14.2%PE39.9x
MRK MerckUS$120.293.4%
+US$9.7b		38.1%PE16.3x
BMY Bristol-Myers SquibbUS$60.655.7%
+US$7.0b		1.8%PE17.6x
PFE PfizerUS$28.084.2%
+US$6.4b		14.4%PE20.6x

Latest News

LLY
US$919.77
Eli Lilly
7D
1.9%
1Y
14.2%
MRK
US$120.29
Merck
7D
3.4%
1Y
38.1%
NMRA
US$1.95
Neumora Therapeutics
7D
-21.1%
1Y
113.5%

Neumora Therapeutics: Downgrading After Navacaprant Development Setback

Mar 30
JNJ
US$244.44
Johnson & Johnson
7D
3.9%
1Y
59.5%

Johnson & Johnson (JNJ): The $100 Billion Revenue Frontier and the MedTech Evolution

Johnson & Johnson (JNJ) is currently trading at $242.83 USD on the NYSE as of the afternoon session on March 30, 2026, reflecting a steady 1% gain for the day. After a transformative 2025 that saw the full integration of its "pure-play" healthcare strategy following the Kenvue spin-off, the company has entered 2026 with significant momentum.
TEVA
US$30.12
Teva Pharmaceutical Industries
7D
3.4%
1Y
97.0%
BMY
US$60.65
Bristol-Myers Squibb
7D
5.7%
1Y
1.8%
ALMS
US$22.03
Alumis
7D
-4.5%
1Y
204.3%
WVE
US$7.25
Wave Life Sciences
7D
-37.7%
1Y
-6.3%
DERM
US$4.69
Journey Medical
7D
-32.1%
1Y
-21.4%

DERM: At The Market Offering And Margin Progress Will Drive Future Upside

Analysts have adjusted their price target for Journey Medical to $13.25 from $13.50, citing updated views on revenue growth, profit margins, and the stock's future P/E multiple as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as reflecting confidence that recent revenue trends and cost controls can support the revised P/E assumption used in their models.
MAZE
US$29.85
Maze Therapeutics
7D
-39.1%
1Y
201.5%
PFE
US$28.08
Pfizer
7D
4.2%
1Y
14.4%
RPRX
US$47.97
Royalty Pharma
7D
5.3%
1Y
53.9%
ELAN
US$23.93
Elanco Animal Health
7D
-3.9%
1Y
131.2%

ELAN: Pet Dermatology Approvals And Q4 Execution May Support Further Upside

Analysts have raised the average price target on Elanco Animal Health to $32 from about $30, citing recent earnings beats, broad-based segment strength, and updated expectations that support a higher fair value along with a materially higher future P/E assumption in their models. Analyst Commentary Recent research points to a clear shift toward more constructive views on Elanco Animal Health, with several bullish analysts raising price targets into the high $20s and low $30s and reaffirming positive ratings following recent results.
LGND
US$199.65
Ligand Pharmaceuticals
7D
-2.4%
1Y
83.6%

LGND: Royalty Portfolio And Phase 3 Readout Will Support Future Upside

Analysts made a small adjustment to Ligand Pharmaceuticals' fair value estimate to $244.50 per share, reflecting updated modeling around its broad royalty portfolio and recent confidence in QTORIN related cash flow potential cited in recent price target and rating updates. Analyst Commentary Recent Street commentary around Ligand Pharmaceuticals centers on the breadth of its royalty portfolio, the progress of QTORIN, and how these factors could influence earnings power and valuation over time.
PBH
US$59.27
Prestige Consumer Healthcare
7D
-4.4%
1Y
-30.9%

PBH: Buybacks And Brand Investment Will Drive Future Shareholder Value

Analysts kept their $77.83 price target for Prestige Consumer Healthcare unchanged, citing stable fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their latest update. What's in the News Completed share repurchase of 3,064,806 shares, or 6.24% of outstanding stock, for a total of US$207 million under the buyback program announced on May 14, 2024.
ZTS
US$118.21
Zoetis
7D
2.0%
1Y
-27.0%

ZTS: Future OA Pain Launch And Buybacks Will Support Medium-Term Upside

Narrative Update The updated analyst price target for Zoetis moves from about $197.51 to $187.59, reflecting analysts' mixed views. Some cite softer organic growth and an innovation "air pocket," while others make smaller price target adjustments.